Photodynamic therapy for early stage bronchogenic carcinoma

J Clin Laser Med Surg. 1996 Oct;14(5):235-8. doi: 10.1089/clm.1996.14.235.

Abstract

Photodynamic therapy utilizing Photofrin has proved to be an effective modality that can be used in the treatment of a wide variety of solid tumors and luminal cancers. The effectiveness of photodynamic therapy (PDT) was demonstrated in our institution in 1980 for the treatment of lung cancers, and increasing attention has been focused on this new treatment technique. Over the past decade, 240 patients (283 lesions) with central type lung cancers have been treated in our hospital. Overall complete remission was obtained in 39.6% of the 112 lesions, partial remission in 59.4%, and no remission was obtained in 1.0%. However, among 95 early stage lesions, CR was obtained in 79 (83.2%) and 71 cases were disease free at 3 to 176 months. We conclude that PDT is efficacious in the treatment of superficial lung cancer where complete remission may be achieved.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenocarcinoma / drug therapy
  • Adult
  • Aged
  • Aged, 80 and over
  • Antineoplastic Agents / therapeutic use*
  • Argon
  • Bronchial Neoplasms / drug therapy
  • Carcinoma, Bronchogenic / drug therapy*
  • Carcinoma, Squamous Cell / drug therapy*
  • Chi-Square Distribution
  • Dihematoporphyrin Ether / therapeutic use*
  • Evaluation Studies as Topic
  • Female
  • Hematoporphyrin Photoradiation*
  • Humans
  • Laser Therapy
  • Male
  • Middle Aged
  • Neoplasm Staging
  • Outcome Assessment, Health Care
  • Remission Induction
  • Survival Analysis
  • Tracheal Neoplasms / drug therapy
  • Ultraviolet Rays

Substances

  • Antineoplastic Agents
  • Argon
  • Dihematoporphyrin Ether